| Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML CD DiNardo, EM Stein, S de Botton, GJ Roboz, JK Altman, AS Mims, ... New England Journal of Medicine 378 (25), 2386-2398, 2018 | 1344 | 2018 |
| Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology MS Tallman, ES Wang, JK Altman, FR Appelbaum, VR Bhatt, D Bixby, ... Journal of the National Comprehensive Cancer Network 17 (6), 721-749, 2019 | 419 | 2019 |
| Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia GJ Roboz, CD DiNardo, EM Stein, S de Botton, AS Mims, GT Prince, ... Blood, The Journal of the American Society of Hematology 135 (7), 463-471, 2020 | 317 | 2020 |
| NCCN guidelines insights: acute myeloid leukemia, version 2.2021: featured updates to the NCCN guidelines DA Pollyea, D Bixby, A Perl, VR Bhatt, JK Altman, FR Appelbaum, ... Journal of the National Comprehensive Cancer Network 19 (1), 16-27, 2021 | 224 | 2021 |
| Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia X Huang, S Schwind, B Yu, R Santhanam, H Wang, P Hoellerbauer, ... Clinical Cancer Research 19 (9), 2355-2367, 2013 | 211 | 2013 |
| Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study EM Stein, CD DiNardo, AT Fathi, AS Mims, KW Pratz, MR Savona, ... Blood, The Journal of the American Society of Hematology 137 (13), 1792-1803, 2021 | 162 | 2021 |
| RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia J Aimiuwu, H Wang, P Chen, Z Xie, J Wang, S Liu, R Klisovic, A Mims, ... Blood, The Journal of the American Society of Hematology 119 (22), 5229-5238, 2012 | 147 | 2012 |
| Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML S Choe, H Wang, CD DiNardo, EM Stein, S de Botton, GJ Roboz, ... Blood advances 4 (9), 1894-1905, 2020 | 143 | 2020 |
| Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial A Burd, RL Levine, AS Ruppert, AS Mims, U Borate, EM Stein, P Patel, ... Nature medicine 26 (12), 1852-1858, 2020 | 126 | 2020 |
| Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged< 60 years AK Eisfeld, J Kohlschmidt, A Mims, D Nicolet, CJ Walker, JS Blachly, ... Leukemia 34 (12), 3215-3227, 2020 | 85 | 2020 |
| Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads … EM Stein, CD DiNardo, AT Fathi, AS Mims, KW Pratz, MR Savona, ... Blood 132, 560, 2018 | 78 | 2018 |
| Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response … TL Lasho, A Mims, MA Elliott, C Finke, A Pardanani, A Tefferi Leukemia 28 (6), 1363-1365, 2014 | 72 | 2014 |
| The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling B Cen, Y Xiong, JH Song, S Mahajan, R DuPont, K McEachern, ... Molecular and cellular biology, 2014 | 71 | 2014 |
| Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia A Mims, AR Walker, X Huang, J Sun, H Wang, R Santhanam, ... Leukemia 27 (4), 871-878, 2013 | 69 | 2013 |
| Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome AS Kittai, DA Bond, B William, A Saad, S Penza, Y Efebera, K Larkin, ... Blood Advances 4 (19), 4648-4652, 2020 | 66 | 2020 |
| Incidence and survival of hematological cancers among adults ages≥ 75 years JL Krok‐Schoen, JL Fisher, JA Stephens, A Mims, S Ayyappan, ... Cancer medicine 7 (7), 3425-3433, 2018 | 66 | 2018 |
| Complete responses in relapsed/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of vibecotamab (XmAb14045), a CD123 x CD3 T cell-engaging bispecific … F Ravandi, A Bashey, W Stock, JM Foran, R Mawad, D Egan, W Blum, ... Blood 136, 4-5, 2020 | 61 | 2020 |
| Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD SA Wall, Q Zhao, M Yearsley, L Blower, A Agyeman, P Ranganathan, ... Blood advances 2 (20), 2619-2628, 2018 | 54 | 2018 |
| Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia TJ Kovacsovics, A Mims, ME Salama, J Pantin, N Rao, KM Kosak, ... Blood advances 2 (4), 381-389, 2018 | 52 | 2018 |
| Complete responses in relapsed/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of XmAb14045, a CD123 x CD3 T cell-engaging bispecific antibody … F Ravandi, A Bashey, JM Foran, W Stock, R Mawad, W Blum, MW Saville, ... Blood 132, 763, 2018 | 51 | 2018 |
